Literature DB >> 22214395

Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein.

John M Knapp1, Alex B Wood, Puay-Wah Phuan, Michael W Lodewyk, Dean J Tantillo, A S Verkman, Mark J Kurth.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The most common CF-causing mutation, ΔF508-CFTR, produces CFTR loss-of-function by impairing its cellular targeting to the plasma membrane and its chloride channel gating. We recently identified cyanoquinolines with both corrector ("Co", normalizing ΔF508-CFTR targeting) and potentiator ("Po", normalizing ΔF508-CFTR channel gating) activities. Here, we synthesized and characterized 24 targeted cyanoquinoline analogues to elucidate the conformational requirements for corrector and potentiator activities. Compounds with potentiator-only, corrector-only, and dual potentiator-corrector activities were found. Molecular modeling studies (conformational search ⇒ force-field lowest energy assessment ⇒ geometry optimization) suggest that (1) a flexible tether and (2) a relatively short bridge between the cyanoquinoline and arylamide moieties are important cyanoquinoline-based CoPo features. Further, these CoPo's may adopt two distinct π-stacking conformations to elicit corrector and potentiator activities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22214395      PMCID: PMC3277286          DOI: 10.1021/jm201372q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

1.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

Authors:  W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

2.  Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.

Authors:  Puay-Wah Phuan; Baoxue Yang; John M Knapp; Alex B Wood; Gergely L Lukacs; Mark J Kurth; A S Verkman
Journal:  Mol Pharmacol       Date:  2011-07-05       Impact factor: 4.436

Review 3.  Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator.

Authors:  W R Skach
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

4.  Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.

Authors:  Aaron D Mills; Choong Yoo; Jeffrey D Butler; Baoxue Yang; A S Verkman; Mark J Kurth
Journal:  Bioorg Med Chem Lett       Date:  2009-11-13       Impact factor: 2.823

5.  Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy.

Authors:  Gui Jun Yu; Choong L Yoo; Baoxue Yang; Michael W Lodewyk; Liping Meng; Tamer T El-Idreesy; James C Fettinger; Dean J Tantillo; A S Verkman; Mark J Kurth
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

6.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

7.  8-hydroxyinoline derivatives. Synthesis and biological evaluation of arylglyoxal N-7-amino-5-substituted 8-hydroxyquinoline hemiacetals and 5-phenylglyoxylidenamin-8-hydroxyquinolines.

Authors:  E Massarani; D Nardi; R Pozzi; L Degen; M J Magistretti
Journal:  J Med Chem       Date:  1970-05       Impact factor: 7.446

8.  Cystic fibrosis: a disease of vulnerability to airway surface dehydration.

Authors:  Richard C Boucher
Journal:  Trends Mol Med       Date:  2007-05-23       Impact factor: 11.951

9.  A mouse model for the delta F508 allele of cystic fibrosis.

Authors:  B G Zeiher; E Eichwald; J Zabner; J J Smith; A P Puga; P B McCray; M R Capecchi; M J Welsh; K R Thomas
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

10.  Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel.

Authors:  Nicoletta Pedemonte; Davide Boido; Oscar Moran; Michele Giampieri; Mauro Mazzei; Roberto Ravazzolo; Luis J V Galietta
Journal:  Mol Pharmacol       Date:  2007-04-23       Impact factor: 4.436

View more
  11 in total

1.  Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Authors:  Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard
Journal:  Br J Pharmacol       Date:  2018-02-22       Impact factor: 8.739

2.  Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.

Authors:  Emily F Kirby; Ashley S Heard; X Robert Wang
Journal:  J Pharmacol Clin Toxicol       Date:  2013-08-28

Review 3.  Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator.

Authors:  James F Collawn; Lianwu Fu; Rafal Bartoszewski; Sadis Matalon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-07-25       Impact factor: 5.464

4.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 5.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

6.  Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein.

Authors:  Lihua He; Pradeep Kota; Andrei A Aleksandrov; Liying Cui; Tim Jensen; Nikolay V Dokholyan; John R Riordan
Journal:  FASEB J       Date:  2012-10-26       Impact factor: 5.191

Review 7.  Molecular basis of cystic fibrosis: from bench to bedside.

Authors:  Maria Cristina Dechecchi; Anna Tamanini; Giulio Cabrini
Journal:  Ann Transl Med       Date:  2018-09

8.  Functional Rescue of F508del-CFTR Using Small Molecule Correctors.

Authors:  Steven Molinski; Paul D W Eckford; Stan Pasyk; Saumel Ahmadi; Stephanie Chin; Christine E Bear
Journal:  Front Pharmacol       Date:  2012-09-26       Impact factor: 5.810

9.  Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines.

Authors:  Jinhong Park; Poonam Khloya; Yohan Seo; Satish Kumar; Ho K Lee; Dong-Kyu Jeon; Sungwoo Jo; Pawan K Sharma; Wan Namkung
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

10.  Davis-Beirut reaction: route to thiazolo-, thiazino-, and thiazepino-2H-indazoles.

Authors:  Kelli M Farber; Makhluf J Haddadin; Mark J Kurth
Journal:  J Org Chem       Date:  2014-07-23       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.